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Abstract
Macrophage migration inhibitory factor (MIF) is an upstream activator of the immune response that
counter-regulates the immunosuppressive effects of glucocorticoids. While MIF is released by cells
in response to diverse microbial and invasive stimuli, evidence that glucocorticoids in low
concentrations also induce MIF secretion suggests an additional regulatory relationship between
these mediators. We investigated the expression of MIF from the human CEM T cell line, which
exists in two well-characterized, glucocorticoid–sensitive (CEM-C7) and glucocorticoid-resistant
(CEM-C1) variant clones. Dexamethasone in low concentrations induced MIF secretion from CEM-
C7 but not CEM-C1 T cells by a bell-shaped dose response that was similar to that reported previously
for the release of MIF by monocytes/macrophages. Glucocorticoid stimulation of CEM-C7 T cells
was accompanied by an MIF transcriptional response, which by promoter analysis was found to
involve the GRE and ATF/CRE transcription factor binding sites. These data support a
glucocorticoid-mediated MIF secretion response by T cells that may contribute to the regulation of
the adaptive immune response.
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Introduction
Macrophage migration inhibitory factor (MIF) is one of the first cytokine activities to be
described 19, yet its upstream role in regulating the immune response has emerged relatively
recently 13. MIF circulates normally in plasma and its levels increase during physiologic stress,
infection, or cancer 9;13. Experimental studies employing recombinant MIF, anti-MIF, or MIF
knockout (MIF-KO) mice have established that this cytokine contributes to the
immunopathogenesis of such disorders as endotoxemia and sepsis 9;16, arthritis 5;34;37,
inflammatory bowel disease 20, asthma 42, and tumor progression 39. Certain of the pro-
inflammatory properties of MIF, whether secreted locally or systemically, have been attributed
to its ability to antagonize the immunosuppressive effects of glucocorticoids 14. MIF regulates
glucocorticoid action by several mechanisms; these include inducing sustained ERK1/2 MAP
kinase activation, which leads to an increase in the translation of cytokine mRNAs 41;57,
inhibiting glucocorticoid-induced expression of the NFκB inhibitor, IκB 18, and inhibiting
glucocorticoid induction of MAP kinase phosphatase (MKP-1), which down-regulates the
responses of the ERK1/2, p38, and JNK MAP kinases 1;24;52.
MIF is released by macrophages, synoviocytes, and neurons upon stimulation with low,
physiologic levels of glucocorticoids14;55;61, and these data are supported by studies of tissue
MIF content after adrenalectomy or glucocorticoid administration 23. Much of the MIF release
response appears to be due to the secretion of protein from preformed, cytoplasmic stores 9;
23;36;45. The observation that glucocorticoids, which are immunosuppressive 50, induce the
release of a counter-regulating mediator such as MIF has focused attention on the role of this
pathway in modulating the immune response 14;24. Of note, MIF normally circulates at its
counter-regulating concentrations (2–10 ng/ml) and blood levels follow a circadian rhythm
that is similar to the diurnal variation in plasma glucocorticoids 48. Whether MIF secretion
from immune cells, the anterior pituitary gland, or other diurnally responsive tissues account
for this circadian rhythm remains unknown 15;29;59; nevertheless, these observations have
led to the concept that MIF and glucocorticoids may act in a regulatory “dyad” to control the
setpoint and the magnitude of the immune response 13;14;24. That MIF functions as a
physiological regulator of glucocorticoid action also has prompted pharmacologic approaches
at targeting MIF for steroid-dependent, chronic inflammatory conditions 12;35;43.
Prior reports of a specific MIF secretion response from monocytes/macrophages stimulated
with low, physiologic levels of glucocorticoids 14 together with increasing evidence that MIF
influences the differentiation of the adaptive T cell response 8;42 prompted us to examine more
closely MIF production by human T cells. We studied MIF protein release and mRNA
expression in the two closely related human T cell lines, CEM-C1 and CEM-C7, which differ
in their sensitivity to glucocorticoid-dependent responses downstream of the glucocorticoid
receptor 58.
Materials and Methods
Cell Lines
The CEM-C1 (clone 15) and CEM-C7 (clone 14) human T cell lines were kindly provided by
Betty H. Johnson (University of Texas, Galveston) and bear the characteristics originally
described by Norman and Thompson46 and Zawydiwski et al.63. The CEM-C7 cells are
diploid, with 11,200±2400 glucocorticoid receptor (GR) sites per cell with a Kd of 13±10 nM,
and are sensitive to killing by 1 µM dexamethasone. The CEM-C1 cells are diploid, with 11,200
±2400 GR sites per cell with a Kd of 12±3 nM, and are resistant to killing by 1 µM
dexamethasone. Cells were maintained in culture with RPMI and 10% FBS.
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Stimulation Studies and MIF Expression Analyses
For stimulation studies, T cells were enumerated, centrifuged, and re-suspended in 48 well
plates at 1×105 cells/ml in RPMI supplemented with 1% heat-inactivated, glucocorticoid-
depleted FBS, as assessed by immunoassay14. Dexamethasone (Sigma, St. Louis, MO) diluted
in RPMI/1% FBS was added at the indicated concentrations and the supernatants removed at
intervals for analysis by MIF ELISA as described previously 4. For RNA analysis, the T cells
were collected by centrifugation and the RNA isolated using RNAeasy (Qiagen, Valencia,
CA). cDNA was synthesized using the ProFirst Strand RT-PCR kit (Stratagene, La Jolla, CA)
at a concentration of 100 ng RNA/µl cDNA 31. The specific primers and reaction conditions
were as follows: MIF forward, 5’-CGGACAGGGTCTACATCAA-3’; MIF reverse, 5’-
CTTAGGCGAAGGTGGAGTT-3’; 18S forward, 5’-GCAATTATTCCCCATGAACG-3’;
18S reverse, ’-TGTACAAAGGGCAGGGACTT-3’. The reactions employed SYBR Green
Supermix (Invitrogen, Carlsbad, CA) and the conditions were: 1 cycle of 95°C for 3 min; 40
cycles of 95°C for 15 sec, followed by 60°C for 1 min; 80 cycles of increasing temperature by
0.5°C, starting at 55°C. The specific amplification of the desired target gene was verified by
the appearance of a single peak in the melting curve at the predicted temperature, and the
appearance of a single band of the predicted length upon gel electrophoresis. Data were
analyzed using the ΔΔCTmethod for relative quantification 33.
Cell Death Detection
Cell death was quantified by ELISA for cytoplasmic histone-associated DNA fragments
(Roche Diagnostics, Indianapolis, IN) 56. Cells were collected at intervals and the cell pellets
lysed by addition of lysis buffer provided in the Roche kit, followed by incubation at 25°C for
30 mins. The lysates were centrifuged at 1500 rpm for 10 min and 20 µl was added to the
ELISA and OD405 recorded. MIF immunoneutralization studies employed the neutralizing
anti-MIF murine IgG1, NIH3D9 20
Construction of a Luciferase Reporter Plasmid Containing the MIF promoter
A 1177 bp long DNA sequence comprising the 5’ flanking sequence upstream of the
transcription start site of the human MIF gene47 was amplified by PCR using the following
oligonucleotides: 5’-CTGCAGGAACCAATACCCAT-3’ and 3’-
CCAGGAAGACGGTAGTACGG-5’. The resultant amplification product was gel-purified
using Geneclean II (BIO 101, La Jolla, CA) and sub-cloned into the Xho/Hind II sites of the
luciferase reporter vector pGL2-Basic (Promega, Madison, WI). The fidelity of construction
of the MIF-luciferase construct was confirmed by DNA sequencing 5.
Site-Directed Mutagenesis
The ATF/CRE binding site (TGGCGTCA, at −116 to −109 bases from the MIF start codon)
and the GRE consensus sequence (AGATGGTCCCC, at −847 to −837 bases) were deleted
from the MIF-luciferase expression plasmid by using the Transformer Site-Directed
Mutagenesis Kit (Clontech, Mountain View, CA). The mutagenic primer, which is homologous
to the wild-type sequence except for the deleted binding site was: ATF/CRE, 5’-
GGCCTGGCGCCGGCGGCAAAAGGCGGGACCAC-3’; and for GRE, 5’-
GATATGCCTGGCACCTGCTGAGTTTACCATTAGTGG-3’. The selection primer, which
converts a single Bam HI site within the vector into a single restriction site for Aat II was: 5’-
CTTATCATGTCTGACGTCGTCGACCGATGC-3’). The primer plasmid annealing reaction
was performed at 100°C for 3 min and 0°C for 5 min in a 20 µl reaction volume containing
0.1 µg pGL2B-MIF DNA, 0.1 µg of the mutagenic primer, 0.1 µg of the selection primer, and
2 µl of 10× annealing buffer. For the synthesis of the mutant strand, 2–4 units of T4 DNA
polymerase, 4–6 units of T4 DNA ligase, 3 µl of 10× synthesis buffer, and 5 µl H2O were
added to the annealing reaction and incubated at 37BC for 2.5 hrs. The synthesized DNA was
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purified with a QIAquick PCR purification kit (Qiagen, Valencia, CA). To reduce the
proportion of the parental DNA (>95% in the total reaction), the DNA then was digested with
BamHI, which linearizes the non-mutated plasmids. Plasmids with an altered unique restriction
site are resistant to digestion by the original enzyme and have a high probability of containing
the desired mutation (the transformation efficiency of the circular mutated plasmid is at least
a 100× higher than that of the linearized parental plasmid). For the restriction digestion, the
purified DNA was incubated with Bam HI, and 10 µl of the restriction digest then were
transformed into competent E. coli BMH 71-18 mutS cells. The plasmid DNA was isolated
with the Qiagen Plasmid Mini Kit. To select for the mutant plasmids, 100 ng of the purified
DNA (total volume 20 µl) was incubated with 20 units Bam HI (NEB), 2 µl 10× NEB react
buffer U, and 0.2 µl 100× BSA for 2 hrs at 37BC. Ten units of fresh enzyme then were added
followed by an additional incubation at 37BC for 1 hr. Five µl of this reaction were transformed
into 100 µl of E.coli DH5α MAX efficiency chemically competent cells (Invitrogen, Carlsbad,
CA). The fidelity of construction was confirmed by bidirectional sequencing of the plasmid
DNA.
Transient Transfection of CEM-C7-cells
The MIF-luciferase reporter plasmid was introduced into CEM-C7 or CEM-C1 T cells by
liposome mediated transfection using the DMRIE-C Reagent (Invitrogen) in OPTI-MEM I
reduced serum medium5. For each transfection, 0.5 ml of media were mixed with 6 µl of
DMRIE-C reagent (2mg/ml) in a polystyrene 6-well plate. After adding plasmid DNA (MIF-
luciferase or vector control) in 0.5 ml OPTI-MEM per well, the plates were incubated at room
temperature for 45 min to allow formation of the lipid-DNA complexes. 2×106 cells in 0.2 ml
OPTI-MEM then were added and the plates were incubated for 6 hrs at 37BC in a 5% CO2
incubator. 2.5 ml of cultivation media was added per well and the cells were incubated for
another 16 hrs before commencing the induction experiments.
For induction of the MIF promoter, the transiently transfected cells were plated in 6-well plates
at a density of 2×106 cells/well in 2 ml of normal growth media and incubated for 12 hrs with
the following agents: dexamethasone (Sigma), phorbol-12-myristate-13-acetate (PMA, give
source), ionomycin (Calbiochem), phytohemagglutinin (PHA), anti-CD3 plus anti-CD28
antibody4, and recombinant human MIF10. Co-transfection studies employing the MIF-
luciferase plasmid and the human glucocorticoid receptor (GR) expression plasmid HGO27
were performed in CEM-C7 T cells at different plasmid ratios (GR expression plasmid : MIF-
luciferase plasmid).
Luciferase Assay
Cells were washed twice in PBS and resuspended in 35 µl of Passive Lysis Buffer (Promega)
per well. After incubation at room temperature for 15 min, the cells were vortexed for 15 sec
and microcentrifuged for 5 min at 12,000×g. The supernatants (i.e. cell lysates) were transferred
into a fresh tube and the luciferase activity measured as follows: 20 µl of the cell lysate was
mixed with 100 µl of Luciferase Assay Reagent (Promega) and the light output measured
immediately with a TD-20/20 luminometer (Promega) with a delay time of 5 sec and an
integration time of 20 sec. The protein concentration of the cell lysates was measured by using
the Bio-Rad DC Protein Assay.
Electrophoretic Mobility Shift Assay (EMSA)
Nuclear extracts were prepared and analyzed by EMSA as previously reported 54. Two µg of
nuclear extracts were incubated for 15 min at room temperature with radio-labeled probes.
Reaction mixtures were electrophoresed through 6% non-denaturing polyacrylamide gels, and
the gels were dried and exposed to X-ray films. The sequence (5’->3’) of the probes were as
follow: ATF/CRE, GGCGCCGGCGGTGGCGTCACAAAA; GRE,
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GGCACCTGCTAGATGGTCCCCGA; ATF/CRE mutant,
GGCGCCGGCGGTGTGTTCACAAAA; and GRE mutant
GGCACCTGCTATATTTTCCCCGA. The EMSA studies were replicated in independent
experiments and the gel data quantified by densitometric analysis as previously described 32.
MIF mRNA Stability
MIF mRNA stability was assessed in CEM-C7 T cells incubated for 4 hrs with dexamethasone
(10−8 M) before the addition of actinomycin D (10 µg/mL) for 0, 1, 3, 5, 7, 9 and 11 hrs. Total
RNA was extracted and processed as previously described 54. MIF-specific mRNA signals
were quantified using an Instant Imager 2024 (Packard, Meriden, CT) and reported relative to
ribosomal RNA level.
Results
MIF Expression by Human CEM-C7 and CEM-C1 T Cells
Glucocorticoids in low physiologic concentrations induce the release of MIF from monocytes/
macrophages14 and other cell types 55;61, and prior studies have shown an increase in MIF
expression in primary T cells and in T cell lines after activation with PHA or anti-CD3 4. To
address whether glucocorticoids also induce MIF expression in T lymphocytes, we studied the
two human T cell lines, CEM-C1 and CEM-C7, which differ in their sensitivity to
glucocorticoids. The CEM-C1 and CEM-C7 cell lines are closely related genetically as they
were cloned from the same individual, but they differ in their responsiveness to glucocorticoids
downstream of the action of the glucocorticoid receptor (GR) 58. The glucocorticoid-sensitive,
CEM-C7 T cell clone undergoes glucocorticoid-dependent apoptosis while the glucocorticoid-
resistant, CEM-C1 T cell clone tolerates concentrations of up to 10−5M of the synthetic
glucocorticoid, dexamethasone.
The CEM-C7 and CEM-C1 T cells were incubated with dexamethasone in the concentration
range of 10−16−10−8M and MIF production assessed by ELISA analysis of the conditioned
medium. As shown in Figure 1, the glucocorticoid-sensitive CEM-C7 T cells but not the
glucocorticoid-resistant CEM-C1 T cells responded to dexamethasone by releasing MIF in a
time-dependent fashion, and increased levels were evident by 2 hrs. MIF release follows a bell-
shaped response curve with respect to the stimulating glucocorticoid concentration, with MIF
detectable at 10−8 M (at 4 hrs), peaking at 10−12 M (at 2 hrs), and then decreasing. These results
agree with data reported in murine monocytes/macrophages, which showed both a similar
threshold and bell-shaped response profile for MIF release when assessed by Western blotting
14.
The rapid release of MIF from CEM-C7 T cells suggested the possibility that MIF was released
from cytoplasmic pools, which exist in several cell types 3;7;15, including T cells, where
intracellular concentrations of 170 fg/cell have been documented in the mouse LBRM T-cell
line 4. Glucocorticoids induce T cell apoptosis 50, which could lead to MIF release; however,
we considered apoptosis to be an unlikely mechanism for MIF appearance in supernatants
given the low concentrations of dexamethasone employed and the longer time course (>20 hrs)
required for apoptosis in CEM-C7 cells 58. We detected low levels of apoptosis (<12%) under
our experimental conditions, which did not correspond to the observed, glucocorticoid-
dependent increases in MIF release (Fig. 1B). ELISA measurement revealed an intracellular
MIF content of ~300 fg/cell in unstimulated CEM-C7 T cells. By calculation therfore, the
glucocorticoid-induced release of MIF from pre-formed intracellular pools may account for
≥85% of the MIF detectable in supernatants, assuming the absence of de novo protein
translation.
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Since MIF is known to protect from activation-induced apoptosis in macrophages 40 and to
promote the survival of B lymphocytes 26, we further assessed whether the neutralization of
secreted MIF influenced baseline apoptotic responses (Fig. 1C). The addition of a neutralizing
anti-MIF monoclonal antibody did not affect the viability of the glucocorticoid-sensitive,
CEM-C7 T cell line after 20 hrs of culture, suggesting that endogenous MIF release conferred
no appreciable effect on cell survival.
We next examined whether the T cell release of MIF was accompanied by a change in steady
state MIF mRNA levels. Using quantitative PCR, and as control, the transcript for long-lived
18S ribosomal RNA, glucocorticoid stimulation was found to result in a significant, dose-
dependent increase in the level of MIF mRNA in the sensitive CEM-C7 T cells but not in the
resistant CEM-C1 T cells (Fig. 2). The highest levels of MIF mRNA were observed at 2 hrs
and at the same dexamethasone concentration (10−12 M) that corresponded with the highest
levels of MIF protein production (Fig. 1A). These data are consistent with the interpretation
that glucocorticoids at low doses lead to a specific induction of both MIF mRNA and protein
expression in the human CEM-C7 T cell line. We also measured the intracytoplasmic content
of MIF in dexamethasone-stimulated T cells as a function of time. While the intracellular
content of MIF of CEM-C7 T cells appeared to fall by 22.4% at 2 hrs, this decrease was not
statistically significant when compared to baseline (0 hrs) or to the MIF content of CEM-C1
T cells (CEM-C7- 0 hrs: 4.9+0.97 µgMIF/g cellular protein vs. 2 hrs: 3.8+0.39 µgMIF/g
cellular protein, P=NS). We conclude that any loss of MIF from intracellular stores is likely
counterbalanced by repletion from newly translated protein.
Glucocorticoid Regulation of MIF Transcription
To begin to investigate regions within the MIF promoter that may be responsible for
glucocorticoid-inducible expression, we examined the promoter sequence for potential
transcription factor binding sites that might be regulated by glucocorticoids. There is a
consensus glucocorticoid responsive element (GRE) 837 nucleotides upstream of the MIF
transcription start site that may interact with the glucocorticoid receptor (GR) DNA binding
domain, and an activating transcription factor/cAMP-response element (ATF/CRE) at position
−109 (Fig. 3A). This later site is influenced by the ATF/CREB family of transcription factors,
whose activity may be regulated by the direct binding of the glucocorticoid receptor to c-Jun
complexes 30 or by glucocorticoid suppression of JNK/SAPK, which phosphorylates c-Jun
and ATF-2 57. We prepared a transfectable reporter plasmid in which the 1177 bp upstream
segment of the MIF promoter was ligated 5’ to the coding region of the luciferase gene.
Luciferase reporter plasmids employing this region of the MIF promoter have been shown to
respond to different transcriptional activators 5;62, and these studies have revealed potential
cell-specific effects 2. A MIF-reporter plasmid (MIF-luciferase) was transfected into several
different human T cell lines to first assess the responsiveness of this construct to the standard
T cell activating stimulus, PMA/ionomycin. Among the different T cell lines tested (Jurkat,
SupT, CEM-C7), the CEM-C7 cell line showed the highest level of induction of luciferase
expression (>5-fold over control, data not shown). Glucocorticoid addition also induced the
expression of luciferase by the MIF promoter in this transfectable, reporter system (Fig. 3B).
Expression levels peaked at 55% over unstimulated controls at a dexamethasone concentration
of 10−8 M. The concentration of dexamethasone that induced optimal expression of the MIF-
luciferase plasmid was higher than that observed for the activation of the endogenous MIF
gene. This discrepancy likely reflects the requirement of additional promoter or enhancer
elements that are not present in the promoter construct. The glucocorticoid-induced expression
of luciferase nevertheless followed a bell-shaped dose-response curve, with expression
decreasing at high glucocorticoid concentrations (>10−8 M). These data support the
interpretation that transcription through the MIF promoter is a control point in the regulation
of MIF expression by T cells and possibly other cell types 55;61.
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To confirm a role for the GR in the transcriptional activation of the MIF promoter, we also
performed co-transfection experiments utilizing the MIF-luciferase plasmid and a human GR
expression plasmid (GR). CEM-C7 T cells co-transfected with an equivalent amount of MIF-
luciferase and GR expression plasmid showed a >25% higher induction of luciferase
expression when compared to cells transfected with MIF-luciferase alone (Fig. 3C). This
enhancement in MIF-luciferase expression increased significantly when the ratio of the GR
expression plasmid to the MIF promoter/luciferase plasmid was increased to ≥10:1.
Role of the GRE and ATF/CRE Sites in the Transcriptional Regulation of the MIF promoter
We synthesized two additional MIF-luciferase reporter plasmids in which the consensus
sequences for the 8 bp ATF/CRE (TGGCGTCA) or the 11 bp GRE (AGATGGTCCCC)
binding sites were selectively deleted (Fig. 4A). Human CEM-C7 T cells transfected with the
reporter construct bearing the ATF-site deletion (MIF-ΔATF/CRE luciferase) showed a 15%
reduction in baseline gene expression and a complete loss of glucocorticoid inducible
expression (Fig. 4B). The reporter construct with the GRE-site deletion (MIF-ΔGRE
luciferase) also showed a 10–15% reduction in baseline expression, and a marked suppression
of glucocorticoid inducibility. While a low level of inducible expression may be detected at
dexamethasone concentrations of >10−6 M (versus 10−4 M), this effect was not statistically
significant. These data indicate that the putative ATF/CRE and GRE sites play a role in
glucocorticoid-regulated MIF expression in CEM-C7 T cells.
Using electrophoretic mobility shift assays (EMSA), we observed that the DNA-binding
activity to the ATF/CRE site increased upon dexamethasone treatment of CEM-C7 T cells
(Figs. 4C, D). This finding is in agreement with the observation that dexamethasone increased
MIF promoter activity in an ATF/CRE site-dependent fashion (Fig. 4B). The GRE site did not
show modulation of DNA binding activity under these experimental conditions, however this
result does not preclude possible effects on the endogenous MIF promoter at the level of
chromatin organization 11.
Glucocorticoids also influence gene expression by regulating the degradation of mRNA 50.
One well-characterized mechanism is by the glucocorticoid regulation of RNA binding proteins
that interact with AU-rich elements that are present in the 3’ UTR of many cytokine transcripts
17;28. MIF lacks such an element 38;47; nevertheless, we assessed the stability of MIF mRNA
under glucocorticoid induction by measuring mRNA levels after addition of the RNA
polymerase inhibitor, actinomycin D. As shown in Fig. 5, dexamethasone did not influence
the turnover of MIF mRNA in T cells under these experimental conditions.
Discussion
The cloning of murine MIF from corticotrophic pituitary cells9 together with the observation
that the circulating level of this cytokine follows a circadian rhythm49 that is influenced by
physiologic stressors14;23 supports the concept that MIF has a close regulatory relationship
with glucocorticoids24. Several of MIF’s pro-inflammatory actions have been attributed to its
ability to counter-regulate the immunosuppressive action of glucocorticoids; among these
regulatory mechanisms are sustained ERK1/2 MAPK activation and inhibition of cytoplasmic
phospholipase A241, prevention of glucocorticoid induction of the NF-κB inhibitor, IκBα18,
and suppression of the glucocorticoid-induced expression of MAPK phosphatase (MKP-1)
52;60. Mice genetically-deficient in MIF also have reduced glucocorticoid levels, which may
be due to the development of these mice in the absence of a physiologic, glucocorticoid counter-
regulator (i.e. MIF) 31.
While glucocorticoids normally suppress the expression of pro-inflammatory cytokines51,
high levels of circulating glucocorticoids have been found to induce MIF expression in the
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thymus and the spleen, which are rich in T cells23. In vitro studies have shown that several
cell types, including monocytes/macrophages, secrete MIF in response to low levels of
glucocorticoids14;55;61. MIF secretion followed a bell-shaped dose-response curve but is
suppressed at high, anti-inflammatory concentrations of glucocorticoids (>10−6M) 14. The
regulated production of MIF at low physiologic levels of glucocorticoids has suggested the
possibility that these steroids exert an important influence on baseline MIF expression, at least
in certain cell types 14;23.
In the present report, we examined MIF production from human CEM T cells, which exist in
two closely related variant clones that are distinguished by glucocorticoid sensitivity (CEM-
C7) and resistance (CEM-C1) 58. Both CEM-C7 and CEM-C1 T cells produce similar
concentrations of the glucocorticoid receptor and show a similar ability to metabolize
dexamethasone. The two cell lines also respond to glucocorticoids by inducing glutamine
synthethase, however CEM-C1 T cells are resistant to dexamethasone-induced apoptosis. It
has been concluded that this cell line manifests a block in a distinctive set of glucocorticoid-
responsive genes, and recent work has revealed specific changes in gene families related to
proliferation, differentiation, and apoptosis 58. We observed that glucocorticoids in low
concentrations (<10−8M) induced MIF secretion as quickly as 2 hours from the sensitive (CEM-
C7) but not the resistant (CEM-C1) T cells. The pattern of MIF secretion also was reminiscent
of the bell-shaped dose-response reported previously for the release of MIF from human or
mouse monocytes/macrophages 14. Of importance, the release of MIF by CEM-C7 T cells was
not accompanied by apoptosis, which could lead to the release of MIF from pre-formed,
intracellular pools 15. These observations suggest a specialized, glucocorticoid-dependent
pathway for MIF release from CEM-C7 T cells.
Further investigations showed that the stimulation of CEM-C7 T cells by glucocorticoids is
associated with a MIF transcriptional response that peaks at 2 hours. Glucocorticoid induction
of MIF expression also was evident by plasmid reporter analysis, with highest expression
observed at a concentration 10−8M dexamethasone. A role for the glucocorticoid receptor in
this transcriptional response was confirmed by co-transfection of a GR expression plasmid,
which enhanced MIF promoter activity in a dose-dependent fashion. We further examined the
role of two potential glucocorticoid-regulatory sites in the transcriptional activation of the
MIF promoter, a consensus GRE site at −837 and an ATF/CRE site at −109. Each site was
deleted and the resulting MIF-luciferase reporter constructs re-studied for MIF expression.
Removal of either the GRE or the ATF/CRE site resulted in a 10–15% reduction in baseline
MIF transcriptional activity and a loss of glucocorticoid inducibility, with the ATF/CRE site
possibly contributing more to glucocorticoid responsiveness than the GRE site. We also
observed that the DNA-binding activity to the MIF ATF/CRE site, but not the GRE site,
increased significantly upon dexamethasone treatment of T cells. Although the GRE site did
not show increased DNA binding activity, we cannot rule out its possible involvement by
epigenetic mechanisms or changes in chromatin organization 11. We also did not observe a
significant affect of glucocorticoids on the stability of MIF mRNA transcripts.
These data provide first insight into the influence of glucocorticoids on MIF transcription, and
they add to the emerging characterization of the MIF promoter. To date, the only response
elements that have been functionally evaluated are a cAMP response element that mediates
constitutive 53 and corticotrophin releasing factor-induced MIF transcription in murine
pituitary cells45;62, and a hypoxia response element that mediates transcriptional activation
by HIF-16.
These data, which were obtained in a well-characterized, glucocorticoid-sensitive human T
cell line, support prior observations that have shown a role for glucocorticoids in the production
of MIF protein from different tissues and cell lines 14;23;55;61. The present findings, as well
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as prior reports, are remarkable in that the release of MIF is observed at concentrations of
glucocorticoids that are at the very low end of glucocorticoid receptor occupancy. This level
of sensitivity may be due in part to the glucocorticoid-free culture conditions employed prior
to stimulation, and it supports an important role for the glucocorticoid receptor in cellular MIF
production. The reporter studies also indicate that MIF transcription is enhanced by increasing
the intracellular content of the glucocorticoid receptor; nevertheless, our data do not rule out
a possible contribution of non-genomic mechanisms for MIF release 50.
MIF is expressed constitutively in many cell types 23. In vivo, high levels of glucocorticoids
increase both circulating MIF concentrations and the MIF content of tissues such as the spleen
and thymus 14;22;49. While prior studies have attributed changes in the MIF content of
different organs to post-transcriptional regulatory mechanisms, the present observations that
MIF release is accompanied by transcriptional activation is noteworthy and point to a role for
glucocorticoids in both constitutive and inducible MIF expression in lymphoid tissue. Our data
thus support two potential mechanisms for the glucocorticoid induced release of MIF. First,
dexamethasone exerts a direct and rapid effect on MIF release from pre-formed, cellular pools.
It is noteworthy that MIF, which lacks an N-terminal leader sequence 10, is released by a
specialized, non-conventional pathway that is mediated by the Golgi-associated protein, p115
36. Activated glucocorticoid receptor complexes thus may initiate MIF secretion by interaction
with components of this pathway. Second, glucocorticoids induce mRNA transcription over a
slightly longer time course by an indirect effect on the GRE.
An increasing literature supports the value of cytokine blockade in different inflammatory and
immunologic diseases21. In the case of MIF, which acts in large measure to counter-regulate
the immunosuppressive properties of glucocorticoids 13;24, it has been hypothesized that
pharmacologic inhibition of MIF may be especially beneficial in those inflammatory
conditions, such as asthma or rheumatoid arthritis, that become refractory to steroid treatment
35;44. Given the observation that MIF expression is itself induced by glucocorticoids14;23 it
is noteworthy that a clinical study in the autoimmune disease systemic lupus erythematosus
has reported a positive correlation between circulating MIF levels and steroid dosage 25. Thus,
the identification of glucocorticoid congeners that retain immunosuppressive but not MIF
stimulatory activity may offer a novel pharmacologic approach for the more efficacious
treatment of inflammatory diseases.
Abbreviations
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FIGURE 1.
A) Dexamethasone induces MIF release from glucocorticoid-sensitive CEM-C7 but not
glucocorticoid-resistant CEM-C1 cells. The two T cell lines (1×105 cells/ml) were cultured
in 48 well plates in RPMI and 1% heat-inactivated, glucocorticoid-depleted FBS, and
dexamethasone added at the indicated concentrations. Supernatants were removed at intervals
for analysis by MIF ELISA. Assays were performed in triplicate, and the results shown are
representative of three experiments.
B) Low concentrations of dexamethasone show negligible effects on CEM-C7 or CEM-
C1 T cell apoptosis. T cells were collected 24 hrs after stimulation with dexamethasone and
apoptosis quantified by ELISA as described in the Methods. The positive control is the ELISA
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value of a corresponding CEM-C7 T cell culture after apoptosis induction. Values shown are
the mean±SD of triplicate measurements. *p<0.05.
C) Immunoneutralization of MIF does not influence baseline apoptosis. CEM-C7 T cells
(1×105/ml) were stimulated with 1x10−12 M dexamethasone in the presence of a neutralizing
anti-MIF mAb or a control IgG1 (both added at 100 µg/ml). Apoptosis was quantified by
ELISA, and data are from replicate experiments,
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FIGURE 2.
Dexamethasone induces MIF mRNA expression from glucocorticoid-sensitive CEMC-7
but not glucocorticoid-resistant CEM-C1 cells. T cells were cultured and stimulated as in
Fig. 1, and the mRNA for MIF isolated at intervals and analyzed by quantitative PCR. The
RNA levels for MIF are expressed relative to 18S ribosomal RNA for the same sample as
described in the Methods. Values are the mean of triplicate determinations, with *p<0.05.
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FIGURE 3.
A) Schematic diagram of the human MIF gene (22q11.2). The upper diagram shows the
three exons, the promoter region, and putative transcription factor binding sites, including the
positions of the GRE and ATF/CRE sites of interest 5.
B) Dexamethasone induces MIF promoter activity in CEM-C7 T cells. Cultured T cells
(2×106 cells/well) were transfected with the MIF-luciferase reporter plasmid and stimulated
with dexamethasone 16 hrs later. Luciferase activity was measured at 12 hrs as described in
the Methods and expressed relative to cellular protein concentration. Data shown are the Mean
±SD from three experiments. *p<0.05.
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C) The glucocorticoid receptor enhances the transcriptional activation of the MIF
Promoter. Cultured CEM-C7 T cells were transfected with the MIF-luciferase reporter
plasmid together with increasing amounts of a GR expression plasmid (GR). Luciferase
expression was measured 12 hrs after the addition of 10−8 M dexamethasone. The values shown
are expressed for the ratio of GR / MIF-luciferase plasmid and show the mean of triplicate
experiments. *p<0.05.
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FIGURE 4.
A) Diagram showing the deleted GRE and ATF/CRE elements used to construct the MIF-
ΔATF/CRE-luciferase and the MIF-ΔGRE-luciferase reporter plasmids. B) Reduced MIF
promoter activity upon deletion of the ATF/CRE or GRE sites. Cultured CEM-C7 T cells
were transfected with the indicated reporter plasmids and the luciferase activity measured 12
hrs later. Values are expressed relative to control plasmid DNA, and are the mean of triplicate
determinations. *p<0.05.
C) Dexamethasone increases DNA binding activity to the ATF/CRE site. Nuclear extracts
from CEM-C7 T cells were incubated for increasing time with 10−8 M dexamethasone and
analyzed by EMSA using radiolabeled ATF/CRE or GRE oligonucleotides. Competition
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analyses were performed by adding 100-fold or 1-fold excess of unlabeled wild-type (WT) or
mutant (MT) oligonucleotides to the reaction mixture. Specific complexes are indicated by the
arrowheads. Results are representative of two independent experiments.
D) Time dependent DNA binding activity at the ATF/CRE and GRE after glucocorticoid
stimulation. Densitometric quantification of the EMSA analyses shown in C) and illustrating
the increase in ATF/CRE but not GRE binding activity at 2 hrs after dexamethasone (10−8 M)
addition.
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FIGURE 5.
Dexamethasone does not influence MIF mRNA stability in human T cells. MIF mRNA
levels in CEM-C7 T cells incubated for 4 hrs with (✠) or without (O) 10−8 M dexamethasone
before the addition of actinomycin D for 0, 1, 3, 5, 7, 9 and 11 hrs. MIF-specific mRNA signals
were quantified relative to ribosomal RNA by image analysis, and the data are expressed as a
percent of the signal present at time 0 (i.e. before the addition of actinomycin D).
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